SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS

Detalhes bibliográficos
Autor(a) principal: Alves, Renato Jorge
Data de Publicação: 2023
Outros Autores: Goncalves, Cezar Emiliano Fernandes
Tipo de documento: Artigo
Idioma: por
Título da fonte: Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online)
Texto Completo: http://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/958
Resumo: Abstract Introduction and objectives: The treatment of dyslipidemia over 75 years old is not well elucidated, due to the non-inclusion in large randomized clinical trials. Elderly people develop atherosclerosis more often and the worldwide population shows greater longevity. To evaluate the efficacy and safety of statin in very elderly people. Methods: The patients were divided into two groups: over 75 years (very elderly) and up to 75 years (control group). We evaluated: coronary artery disease (CAD); stroke; clearance of creatinine; creatine phosphokinase (CPK) and transaminase (ALT, AST) levels; lipid profile; type, dosage, and time using a statin. Results: The sample of 120 patients, 53,2% male, age 74.1 (±11.1) years, 82.3 very elderly, and 64.9 years in the control group. The total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL-C) in very elderly and control were 162 and 166 (p=ns), 84 and 90 (p=ns), 52.5 and 47 mg/dL (p=0.07), respectively. CAD and stroke, respectively 52.5 and 78.8% (p=0.007), and 18.6 and 7.7% (p=0.09). The time using a statin and the number of drugs taken were the same in the groups. The CPK and ALT levels were 97 and 110 (p=ns) and 16.5 and 20 U/L (p=0.004), respectively. There was no statin dose reduction in the elderly group despite the higher proportion of clinical comorbidities or renal dysfunction. Conclusions: The statin treatment in very elderly patients is effective and safe. The increased risk of CAD and stroke in elderly people corroborate the importance of statin use in this age group.
id FCMSCSP_820fe4efbf8b564e4ab5c0ea91dbd11d
oai_identifier_str oai:ojs2.arquivosmedicos.fcmsantacasasp.edu.br:article/958
network_acronym_str FCMSCSP
network_name_str Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online)
repository_id_str
spelling SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOSSafety and efficacy of statin treatment in very elderly patients / Segurança e eficácia do tratamento com estatinas em pacientes muito idososAbstract Introduction and objectives: The treatment of dyslipidemia over 75 years old is not well elucidated, due to the non-inclusion in large randomized clinical trials. Elderly people develop atherosclerosis more often and the worldwide population shows greater longevity. To evaluate the efficacy and safety of statin in very elderly people. Methods: The patients were divided into two groups: over 75 years (very elderly) and up to 75 years (control group). We evaluated: coronary artery disease (CAD); stroke; clearance of creatinine; creatine phosphokinase (CPK) and transaminase (ALT, AST) levels; lipid profile; type, dosage, and time using a statin. Results: The sample of 120 patients, 53,2% male, age 74.1 (±11.1) years, 82.3 very elderly, and 64.9 years in the control group. The total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL-C) in very elderly and control were 162 and 166 (p=ns), 84 and 90 (p=ns), 52.5 and 47 mg/dL (p=0.07), respectively. CAD and stroke, respectively 52.5 and 78.8% (p=0.007), and 18.6 and 7.7% (p=0.09). The time using a statin and the number of drugs taken were the same in the groups. The CPK and ALT levels were 97 and 110 (p=ns) and 16.5 and 20 U/L (p=0.004), respectively. There was no statin dose reduction in the elderly group despite the higher proportion of clinical comorbidities or renal dysfunction. Conclusions: The statin treatment in very elderly patients is effective and safe. The increased risk of CAD and stroke in elderly people corroborate the importance of statin use in this age group.AbstractIntroduction and objectives: The treatment of dyslipidemia over 75 years old is not well elucidated, dueto the non-inclusion in large randomized clinical trials. The elderly people develop atherosclerosis more often and the worldwide population shows greater longevity. To evaluate the efficacy and safety of statin in very elderly people. Methods: The patients were divided into two groups: over 75 years (very elderly) and up to 75 years (control group). We evaluated: coronary artery disease (CAD); stroke; clearance of creatinine; creatine phosphokinase (CPK) and transaminase (ALT, AST) levels; lipid profile; type, dosage, and time using statin. Results: Sample of 120 patients, 53,2% male, age 74.1 (±11.1) years, 82.3 very elderly and 64.9 years the control group. The total cholesterol, low density lipoprotein cholesterol (LDL-C) and high-density lipoprotein (HDL-C) in very elderly and control were 162and 166 (p=ns), 84 and 90 (p=ns), 52.5 and 47 mg/dL (p=0.07), respectively. CAD and stroke, respectively 52.5and 78.8% (p=0.007), and 18.6 and 7.7% (p=0.09). The time using statin and number of drugs taken were thesame in the groups. The CPK and ALT levels were 97 and 110 (p=ns) and 16.5 and 20 U/L (p=0.004), respectively.There was no statin dose reduction in the very elderly group despite the higher proportion of clinical comorbidities or renal dysfunction. Conclusions: The statin treatment in very elderly patients is effective and safe. The increased risk of CAD and stroke in very elderly people corroborates the importance of statin use in this age group.Keywords: Statin, Dyslipidemia, Patients, Elderly ResumoIntrodução e objetivos: O tratamento da dislipidemia acima de 75 anos não está bem elucidado, devido à nãoinclusão em grandes ensaios clínicos randomizados. Os idosos desenvolvem aterosclerose com maior frequênciae a população mundial apresenta maior longevidade. Nosso objetivo foi avaliar a eficácia e a segurança daestatina em pessoas muito idosas. Métodos: Os pacientes foram divididos em dois grupos: acima de 75 anos (muitoidosos) e até 75 anos (grupo controle). Avaliamos: doença arterial coronariana (DAC); Acidente Vascular Cerebral(AVC); depuração de creatinina; níveis de creatina fosfoquinase (CPK) e transaminase (ALT); perfil lipídico;tipo, dosagem e tempo de uso da estatina. Resultados: Amostra de 120 pacientes, 53,2% do sexo masculino, idade74,1 ± 11,1 anos, 82,3 muito idosos e 64,9 anos o grupo controle. Colesterol total, colesterol de lipoproteína de baixadensidade (LDL-C) e de lipoproteína de alta densidade (HDL-C) em muito idosos e controle foram 162 e 166 (p=ns),84 e 90 (p=ns), 52,5 e 47 mg/dL (p=0,07), respectivamente. DAC e AVC, respectivamente 52,5 e 78,8% (p=0,007), e 18,6e 7,7% (p=0,09). O tempo de uso da estatina e o número de medicamentos tomados foram iguais nos dois grupos.Os níveis de CPK e ALT foram 97 e 110 (p=ns) e 16,5 e 20 U/L (p=0,004), respectivamente. Não houve redução dadose de estatina no grupo de muito idosos, apesar da maior proporção de comorbidades clínicas ou disfunção renal. Conclusões: O tratamento com estatina em pacientes muito idosos é eficaz e seguro. O risco aumentado de DAC e AVC em pessoas muito idosas corrobora a importância do uso de estatinas nessa faixa etária.Palavras-chave: Estatina, Dislipidemias, Paciente, Idosos  Faculdade de Ciências Médicas da Santa Casa de São Paulo2023-03-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/95810.26432/1809-3019.2024.69.002Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo; V. 69 (2024): Jan/Dez; 1 of 91809-30190101-6067reponame:Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online)instname:Faculdade de Ciências Médicas da Santa Casa de São Pauloinstacron:FCMSCSPporhttp://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/958/1232Copyright (c) 2023 Renato Jorge Alves, Cezar Emiliano Fernandes Goncalveshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAlves, Renato JorgeGoncalves, Cezar Emiliano Fernandes2024-04-03T15:01:33Zoai:ojs2.arquivosmedicos.fcmsantacasasp.edu.br:article/958Revistahttp://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSPONGhttp://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/oaiarquivosmedicos@fcmsantacasasp.edu.br||1809-30190101-6067opendoar:2024-04-03T15:01:33Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online) - Faculdade de Ciências Médicas da Santa Casa de São Paulofalse
dc.title.none.fl_str_mv SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
Safety and efficacy of statin treatment in very elderly patients / Segurança e eficácia do tratamento com estatinas em pacientes muito idosos
title SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
spellingShingle SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
Alves, Renato Jorge
title_short SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
title_full SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
title_fullStr SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
title_full_unstemmed SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
title_sort SEGURANÇA E EFICÁCIA DO TRATAMENTO COM ESTATINAS EM PACIENTES MUITO IDOSOS
author Alves, Renato Jorge
author_facet Alves, Renato Jorge
Goncalves, Cezar Emiliano Fernandes
author_role author
author2 Goncalves, Cezar Emiliano Fernandes
author2_role author
dc.contributor.author.fl_str_mv Alves, Renato Jorge
Goncalves, Cezar Emiliano Fernandes
description Abstract Introduction and objectives: The treatment of dyslipidemia over 75 years old is not well elucidated, due to the non-inclusion in large randomized clinical trials. Elderly people develop atherosclerosis more often and the worldwide population shows greater longevity. To evaluate the efficacy and safety of statin in very elderly people. Methods: The patients were divided into two groups: over 75 years (very elderly) and up to 75 years (control group). We evaluated: coronary artery disease (CAD); stroke; clearance of creatinine; creatine phosphokinase (CPK) and transaminase (ALT, AST) levels; lipid profile; type, dosage, and time using a statin. Results: The sample of 120 patients, 53,2% male, age 74.1 (±11.1) years, 82.3 very elderly, and 64.9 years in the control group. The total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL-C) in very elderly and control were 162 and 166 (p=ns), 84 and 90 (p=ns), 52.5 and 47 mg/dL (p=0.07), respectively. CAD and stroke, respectively 52.5 and 78.8% (p=0.007), and 18.6 and 7.7% (p=0.09). The time using a statin and the number of drugs taken were the same in the groups. The CPK and ALT levels were 97 and 110 (p=ns) and 16.5 and 20 U/L (p=0.004), respectively. There was no statin dose reduction in the elderly group despite the higher proportion of clinical comorbidities or renal dysfunction. Conclusions: The statin treatment in very elderly patients is effective and safe. The increased risk of CAD and stroke in elderly people corroborate the importance of statin use in this age group.
publishDate 2023
dc.date.none.fl_str_mv 2023-03-28
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/958
10.26432/1809-3019.2024.69.002
url http://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/958
identifier_str_mv 10.26432/1809-3019.2024.69.002
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv http://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/958/1232
dc.rights.driver.fl_str_mv Copyright (c) 2023 Renato Jorge Alves, Cezar Emiliano Fernandes Goncalves
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Renato Jorge Alves, Cezar Emiliano Fernandes Goncalves
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Faculdade de Ciências Médicas da Santa Casa de São Paulo
publisher.none.fl_str_mv Faculdade de Ciências Médicas da Santa Casa de São Paulo
dc.source.none.fl_str_mv Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo; V. 69 (2024): Jan/Dez; 1 of 9
1809-3019
0101-6067
reponame:Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online)
instname:Faculdade de Ciências Médicas da Santa Casa de São Paulo
instacron:FCMSCSP
instname_str Faculdade de Ciências Médicas da Santa Casa de São Paulo
instacron_str FCMSCSP
institution FCMSCSP
reponame_str Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online)
collection Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online)
repository.name.fl_str_mv Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo (Online) - Faculdade de Ciências Médicas da Santa Casa de São Paulo
repository.mail.fl_str_mv arquivosmedicos@fcmsantacasasp.edu.br||
_version_ 1797067817530425344